+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Cotreatment with growth hormone after pituitary suppression for ovarian stimulation in in vitro fertilization a randomized double blind placebo control trial



Cotreatment with growth hormone after pituitary suppression for ovarian stimulation in in vitro fertilization a randomized double blind placebo control trial



Fertility & Sterility 56(6): 1104-1110



Objective: To explore the effect of cotreatment with growth hormone (GH) for ovarian stimulation after pituitary suppression. Design: A randomized, double-blind, placebo-controlled study. Setting: Specialist Reproductive Endocrine and In Vitro Fertilization (IVF) Unit. Patients, Participants: Twenty-five IVF patients who had responded suboptimally in a previous treatment cycle. A subgroup of 18 patients were found have ultrasound (US) findings of polycystic ovaries (PCO). Main Outcome Measure: The amount of gonadotropin used, development of follicles .gtoreq. 14 mm, number of oocytes collected, fertilized, cleaved and replaced, serum and follicular fluid (FF) insulin-like growth factor I (IGF-I) concentrations. Results: Cotreatment with GH was associated with a significant reduction in gonadotropins requirement (P < 0.05). In patients with US-diagnosed PCO more follicles developed (P < 0.05), more oocytes were collected (P < 0.03), fertilized (P < 0.004), and cleaved (P < 0.02). A significantly higher FF IGF-I concentrations were found in patients receiving cotreatment with GH compared with those who received placebo (P < 0.04). Conclusions: We believe that there may be a place for GH treatment in selected IVF cycles after pituitary suppression but what the role of IGF-I is should further be investigated.

Please choose payment method:






(PDF emailed within 1 workday: $29.90)

Accession: 007165719

Download citation: RISBibTeXText

PMID: 1743329


Related references

Cotreatment with growth hormone, after pituitary suppression, for ovarian stimulation in in vitro fertilization: A randomized, double-blind, placebo-control trial. International Journal of Gynecology & Obstetrics 38(4): 338-0, 1992

Cotreatment with growth hormone, after pituitary suppression, for ovarian stimulation in in vitro fertilization: a randomized, double-blind, placebo-control trial**Presented in part at the 2nd International Symposium on Gonadotropin-releasing Hormone Analoges in Cancer and Human Reproduction, Geneva, Switzerland, November 7 to 10, 1990. Fertility and Sterility 56(6): 1104-1110, 1991

Large, comparative, randomized double-blind trial confirming noninferiority of pregnancy rates for corifollitropin alfa compared with recombinant follicle-stimulating hormone in a gonadotropin-releasing hormone antagonist controlled ovarian stimulation protocol in older patients undergoing in vitro fertilization. Fertility and Sterility 104(1): 94-103.E1, 2015

Effect of cotreatment with growth hormone on ovarian stimulation in poor responders to in vitro fertilization. Fertility and Sterility 79(5): 1251-1253, 2003

The effect of growth hormone supplementation on in vitro fertilization outcome: a prospective randomized placebo-controlled double-blind study*. Fertility and Sterility 58(3): 575-580, 1992

The effect of growth hormone supplementation on in vitro fertilization outcome a prospective randomized placebo controlled double blind study. Fertility & Sterility 58(3): 575-580, 1992

Adjuvant growth hormone therapy in poor responders to in-vitro fertilization: A prospective randomized placebo-controlled double-blind study. Human Reproduction (Oxford) 10(1): 40-43, 1995

Follicle-stimulating hormone administered at the time of human chorionic gonadotropin trigger improves oocyte developmental competence in in vitro fertilization cycles: a randomized, double-blind, placebo-controlled trial. Fertility and Sterility 95(5): 1655-1660, 2011

A randomized comparison of two ovarian stimulation protocols with gonadotropin-releasing hormone (GnRH) antagonist cotreatment for in vitro fertilization commencing recombinant follicle-stimulating hormone on cycle day 2 or 5 with the standard long GnRH agonist protocol. Journal of Clinical Endocrinology and Metabolism 88(1): 166-173, 2003

A randomized comparison of two ovarian stimulation protocols with gonadotropin-releasing hormone (GnRH) antagonist cotreatment for in vitro fertilization commencing recombinant follicle-stimulating hormone on cycle day 2 or 5 with the standard long GnRH agonist protocol. Journal of Clinical Endocrinology and Metabolism 88(9): 4510; Author Reply 4510-1, 2003

A double-blind cross-over controlled study to evaluate the effect of human biosynthetic growth hormone on ovarian stimulation in previous poor responders to in-vitro fertilization. Human Reproduction 9(1): 13-18, 1994

Effects of estradiol injection on outcome of in-vitro fertilization: a randomized, double-blind, placebo controlled trial. Clinical and Experimental Obstetrics and Gynecology 43(6): 875-879, 2016

Ovulation induction in premature ovarian failure: a placebo-controlled randomized trial combining pituitary suppression with gonadotropin stimulation. Fertility and Sterility 64(2): 273-278, 1995

Randomized trial of three luteinizing hormone releasing hormone analogues used for ovarian stimulation in an in vitro fertilization program. Fertility & Sterility 57(6): 1265-1268, 1992

Effect of growth hormone treatment on testicular function, puberty, and adrenarche in boys with non-growth hormone-deficient short stature: a randomized, double-blind, placebo-controlled trial. Journal of Pediatrics 138(3): 406-410, 2001